RT Journal Article
SR Electronic
T1 Pediatric multiple sclerosis
JF Neurology
JO Neurology
FD Lippincott Williams & Wilkins
SP S103
OP S109
DO 10.1212/WNL.0000000000002884
VO 87
IS 9 Supplement 2
A1 Chitnis, Tanuja
A1 Ghezzi, Angelo
A1 Bajer-Kornek, Barbara
A1 Boyko, Alexey
A1 Giovannoni, Gavin
A1 Pohl, Daniela
YR 2016
UL http://n.neurology.org/content/87/9_Supplement_2/S103.abstract
AB Over the last 20 years, there have been significant advances in multiple sclerosis (MS) therapeutics, with regulatory approval for 13 therapies in adults by the European Medicines Agency (EMA) and Food and Drug Administration. However, there is only limited approval for interferon-β and glatiramer acetate use in children 12 years and older by the EMA. Availability of disease-modifying therapies to children and adolescents with MS is variable by region, and is extremely limited in some regions of the world. Up to 30% of children experience breakthrough disease requiring therapies beyond traditional first-line agents. Recent legislation in both the United States and Europe has mandated clinical studies for all new therapeutics applicable to children. Several clinical trials in children are underway that will provide important information regarding the efficacy and safety of newer drugs. This review summarizes the current knowledge of breakthrough disease, escalation, and induction treatment approaches in children with MS, especially pertaining to disease course and disability outcomes in this group of patients. In addition, ongoing clinical trials and approaches and challenges in conducting clinical trials in the pediatric population are discussed.AOMS=adult-onset multiple sclerosis; ARR=annualized relapse rate; CI=confidence interval; EDSS=Expanded Disability Status Scale; EMA=European Medicines Agency; FDA=Food and Drug Administration; GA=glatiramer acetate; IFN=interferon; IPMSSG=International Pediatric MS Study Group; JCV=JC virus; MS=multiple sclerosis; NEDA=no evident disease activity; NMO=neuromyelitis optica; PIP=Pediatric Investigation Plan; PML=progressive multifocal leukoencephalopathy; POMS=pediatric-onset multiple sclerosis; PREA=Pediatric Research Equity Act